GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » Operating Income

LifeTech Scientific (HKSE:01302) Operating Income : HK$322 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific Operating Income?

LifeTech Scientific's Operating Income for the six months ended in Dec. 2023 was HK$81 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$322 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. LifeTech Scientific's Operating Income for the six months ended in Dec. 2023 was HK$81 Mil. LifeTech Scientific's Revenue for the six months ended in Dec. 2023 was HK$687 Mil. Therefore, LifeTech Scientific's Operating Margin % for the quarter that ended in Dec. 2023 was 11.84%.

Good Sign:

LifeTech Scientific Corp operating margin is expanding. Margin expansion is usually a good sign.

LifeTech Scientific's 5-Year average Growth Rate for Operating Margin % was 11.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LifeTech Scientific's annualized ROC % for the quarter that ended in Dec. 2023 was 7.02%. LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.50%.


LifeTech Scientific Operating Income Historical Data

The historical data trend for LifeTech Scientific's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific Operating Income Chart

LifeTech Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.41 48.70 400.00 383.01 322.07

LifeTech Scientific Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.19 234.95 159.18 240.80 81.28

LifeTech Scientific Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$322 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LifeTech Scientific  (HKSE:01302) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LifeTech Scientific's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=162.55 * ( 1 - -30.09% )/( (2707.645 + 3316.14)/ 2 )
=211.461295/3011.8925
=7.02 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4464.701 - 679.526 - ( 1077.53 - max(0, 694.36 - 2115.927+1077.53))
=2707.645

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5136.784 - 530.737 - ( 1289.907 - max(0, 842.358 - 2440.377+1289.907))
=3316.14

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-95.92/( ( (913.793 + max(338.504, 0)) + (1007.876 + max(296.696, 0)) )/ 2 )
=-95.92/( ( 1252.297 + 1304.572 )/ 2 )
=-95.92/1278.4345
=-7.50 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(171.166 + 371.389 + 478.614) - (679.526 + 0 + 3.139)
=338.504

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(115.049 + 528.957 + 488.165) - (530.737 + 0 + 304.738)
=296.696

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

LifeTech Scientific's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=81.275/686.532
=11.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


LifeTech Scientific Operating Income Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeTech Scientific (HKSE:01302) Business Description

Traded in Other Exchanges
Address
No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures minimally invasive medical devices for cardiovascular and vascular diseases. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Executives
Xie Yuehui 2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Bank Of Communications Trustee Limited 2301 Trustee
Xie Yuehui 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner

LifeTech Scientific (HKSE:01302) Headlines

No Headlines